Loading news...
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Risk and Volatility DiaSorin has a beta of 0.1,
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Risk and Volatility DiaSorin has a beta of 0.12,
Invesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter. We are benchmark independent, bottom-up investors, focusing on company fundamentals rather than using a “top-down” perspective to overweight or underweight any sector or region. We exited AIA Engineering, Belimo, Epiroc, Japan Elevator Service, Kardex, Konami, and Triveni Turbine.
DiaSorin's 2024 revenue grew by 3%, with an underlying increase of 7%, and net profit rose to 188.1M EUR, reflecting a 17% EPS increase. The company generated strong free cash flow of 191M EUR, enabling potential M&A activities to support future growth. DiaSorin's 2025 guidance targets a 7% revenue increase and a 34% adjusted EBITDA margin, with plans to reach a 36-37% margin by 2027.
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2024 Results Conference Call March 14, 2025 12:30 PM ET Company Participants Carlo Rosa - CEO Piergiorgio Pedron - CFO Conference Call Participants Kavya Deshpande - UBS Maja Pataki - Kepler Aisyah Noor - Morgan Stanley Dylan van Haaften - Stifel Odysseas Manesiotis - BNP Paribas Natalia Webster - RBC Capital Markets Jan Koch - Deutsche Bank Shubhangi Gupta - HSBC Operator Good afternoon.
Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2024 Earnings Conference Call July 29, 2024 11:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conference Call Participants Kavya Deshpande - UBS Marianne Bulot - Bank of America Odysseas Manesiotis - Berenberg Shubhangi Gupta - HSBC Aisyah Noor - Morgan Stanley Hugo Solvet - BNP Paribas Maja Stephanie Pataki - Kepler Cheuvreux Ana Bain - Barclays Giorgio Tavolini - Intermonte Sim Operator Good afternoon.
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.
T, DSRLF and HAFC have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2023.
DiaSorin S.p.A. (OTCPK:DSRLF) Q3 2023 Earnings Conference Call November 3, 2023 11:30 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conference Call Participants Odysseas Manesiotis - Berenberg Maja Pataki - Kepler Cheuvreux Aisyah Noor - Morgan Stanley Operator Good afternoon.
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conference Call Participants Shubhangi Gupta - HSBC Maja Pataki - Kepler Cheuvreux Aisyah Noor - Morgan Stanley Hugo Solvet - BNP Paribas Exane Louise Boyer - Stifel Odysseas Manesiotis - Berenberg Operator Good afternoon.
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2022 Earnings Conference Call March 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conference Call Participants Odysseas Manesiotis - Berenberg Maja Pataki - Kepler Cheuvreux Aisyah Noor - Morgan Stanley Shubhangi Gupta - HSBC Hugo Solvet - Exane BNP Paribas Emanuele Gallazzi - Equita SIM Operator Good afternoon.
DiaSorin S.p.A. is an Italian healthcare company that develops, produces, and sells reagent kits and analyzer instruments mostly used to detect patients' diseases. DiaSorin benefited from the outbreak of the covid pandemic which heavily increased the number of diagnostic tests carried out to track the spread of the pandemic.
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2022 Earnings Conference Call August 3, 2022 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conference Call Participants Emanuele Gallazzi - Equita.
DiaSorin S.p.A. (OTCPK:DSRLF) Q1 2022 Earnings Conference Call May 6, 2022 11:30 AM ET Company Participants Carlo Rosa – Chief Executive Officer Piergiorgio Pedron – Chief Financial Officer Conference Call Participants Maja Pataki – Kepler Hugo Solvet – BNP Paribas Exane Peter Welford – Jefferies Giorgio Tavolini – Intermonte Operator Good afternoon.
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript
Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp demand for tests, sending shares down more than 11%.
QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa On Q3 2021 Results - Earnings Call Transcript